ConductScience.org, home

Paper2863676

Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.

Auerbach HS and 3 others. Lancet, 1985. Cited by 279 papers, by iCite.

Cite this record

ConductScience Library. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Papers, record 2863676. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2863676

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.
PubMed
Journal
Lancet
PubMed
Year
1985
PubMed
Publication types
Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
279
iCite
Relative citation ratio, by iCite
10.3
iCite
Revised in PubMed
2019-06-11
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Auerbach HSH S
2Williams MM
3Kirkpatrick JAJ A
4Colten HRH R

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cystic FibrosisMajor topic
PrednisoneMajor topic
RespirationMajor topic
Body Height
Body Weight
Child
Child, Preschool
Clinical Trials as Topic
Double-Blind Method
Drug Administration Schedule
Humans
Immunoglobulin G
Infant
Pulmonary Ventilation
Random Allocation
Vital Capacity

Source PubMed

Download CSV of topics

Cited by78

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 279 citations.

PMIDTitleJournalYearIn PapersSource
38096105Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.Ann Am Thorac Soc2024https://conductscience.org/library/papers/38096105PubMed
36149378Appetite stimulants for people with cystic fibrosis.Cochrane Database Syst Rev2022https://conductscience.org/library/papers/36149378PubMed
33935699Cystic Fibrosis Lung Disease in the Aging Population.Front Pharmacol2021https://conductscience.org/library/papers/33935699PubMed
32848733Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies.Front Pharmacol2020https://conductscience.org/library/papers/32848733PubMed
32288449Infections in cystic fibrosis.Semin Pediatr Infect Dis1995https://conductscience.org/library/papers/32288449PubMed
31813753Strong toll-like receptor responses in cystic fibrosis patients are associated with higher lung function.J Cyst Fibros2020https://conductscience.org/library/papers/31813753PubMed
29922157Opposite Expression of Hepatic and Pulmonary Corticosteroid-Binding Globulin in Cystic Fibrosis Patients.Front Pharmacol2018https://conductscience.org/library/papers/29922157PubMed
28656134Corticosteroid-resistant inflammatory signalling in Pseudomonas-infected bronchial cells.ERJ Open Res2017https://conductscience.org/library/papers/28656134PubMed
28559270Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation.Antimicrob Agents Chemother2017https://conductscience.org/library/papers/28559270PubMed
27347364Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications.Ther Adv Chronic Dis2016https://conductscience.org/library/papers/27347364PubMed
27189798Cystic fibrosis.Nat Rev Dis Primers2015https://conductscience.org/library/papers/27189798PubMed
26747453Current and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its Symptoms.Drugs R D2016https://conductscience.org/library/papers/26747453PubMed
26649765Oral steroids for long-term use in cystic fibrosis.Cochrane Database Syst Rev2015https://conductscience.org/library/papers/26649765PubMed
23880054Antibiotic and anti-inflammatory therapies for cystic fibrosis.Cold Spring Harb Perspect Med2013https://conductscience.org/library/papers/23880054PubMed
22481418Cystic fibrosis: a mucosal immunodeficiency syndrome.Nat Med2012https://conductscience.org/library/papers/22481418PubMed
22105373Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.Eur J Clin Pharmacol2012https://conductscience.org/library/papers/22105373PubMed
22096358Potential of anti-inflammatory treatment for cystic fibrosis lung disease.J Inflamm Res2010https://conductscience.org/library/papers/22096358PubMed
21500868Targeting airway inflammation in cystic fibrosis in children: past, present, and future.Paediatr Drugs2011https://conductscience.org/library/papers/21500868PubMed
21454676Down-regulation of cytokine-induced interleukin-8 requires inhibition of p38 mitogen-activated protein kinase (MAPK) via MAPK phosphatase 1-dependent and -independent mechanisms.J Biol Chem2011https://conductscience.org/library/papers/21454676PubMed
21233507Clinical significance of microbial infection and adaptation in cystic fibrosis.Clin Microbiol Rev2011https://conductscience.org/library/papers/21233507PubMed

See all 78 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2863676

GET https://conductscience.org/api/papers/v1/2863676/cited_by?page=2